288 related articles for article (PubMed ID: 7769190)
41. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
Feurle GE; Helmstädter V
Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
[No Abstract] [Full Text] [Related]
42. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
43. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
44. [Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid].
Maier K; Frühmorgen P; Bode JC; Heller T; von Gaisberg U; Klotz U
Dtsch Med Wochenschr; 1985 Mar; 110(10):363-8. PubMed ID: 2857633
[TBL] [Abstract][Full Text] [Related]
45. Medical therapy for Crohn's disease: the state of the art.
Stein RB; Lichtenstein GR
Surg Clin North Am; 2001 Feb; 81(1):71-101, viii. PubMed ID: 11218170
[TBL] [Abstract][Full Text] [Related]
46. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
Bayerdörffer E; Bock H
Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251
[TBL] [Abstract][Full Text] [Related]
47. [Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid].
Fahrländer H
Schweiz Med Wochenschr; 1987 Oct; 117(42):1620-3. PubMed ID: 3321418
[TBL] [Abstract][Full Text] [Related]
48. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
49. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Brookes MJ; Green JR
Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
[TBL] [Abstract][Full Text] [Related]
50. The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease.
Seo M; Okada M; Yao T; Furukawa H; Matake H
J Clin Gastroenterol; 1999 Oct; 29(3):270-5. PubMed ID: 10509955
[TBL] [Abstract][Full Text] [Related]
51. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.
Tung J; Loftus EV; Freese DK; El-Youssef M; Zinsmeister AR; Melton LJ; Harmsen WS; Sandborn WJ; Faubion WA
Inflamm Bowel Dis; 2006 Dec; 12(12):1093-100. PubMed ID: 17119382
[TBL] [Abstract][Full Text] [Related]
52. Newer treatments for inflammatory bowel disease.
Stotland BR; Lichtenstein GR
Prim Care; 1996 Sep; 23(3):577-608. PubMed ID: 8888346
[TBL] [Abstract][Full Text] [Related]
53. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
54. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.
Lauritsen K; Staerk Laursen L; Bukhave K; Rask-Madsen J
Gut; 1988 Jul; 29(7):974-82. PubMed ID: 2840367
[TBL] [Abstract][Full Text] [Related]
55. [Current medical therapies for Crohn's disease in Japan].
Munakata A; Haga Y
Nihon Geka Gakkai Zasshi; 1997 Apr; 98(4):406-11. PubMed ID: 9168493
[TBL] [Abstract][Full Text] [Related]
56. Drug therapy for inflammatory bowel disease: Part II.
Linn FV; Peppercorn MA
Am J Surg; 1992 Aug; 164(2):178-85. PubMed ID: 1636900
[TBL] [Abstract][Full Text] [Related]
57. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
58. [Management of ulcerative colitis].
Rammert Ch; Kullak-Ublick GA
Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
[TBL] [Abstract][Full Text] [Related]
59. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
60. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
